Susceptibility of the prostate cancer cell to different physical, hormonal, and chemical agents: present status and theoretical prospects for improved prostate cancer therapy.
The benefits and limitations of present modes of treatment of prostatic cancer with physical, hormonal, and chemical agents are briefly reviewed. The theoretical possibility that the heterogeneous clones that comprise prostatic cancer might be killed or controlled by selective targeting of cytotoxic agents (actual or potential) to malignant cells is discussed in terms of two types of delivery vehicles to provide for cell selectivity: (1) monoclonal antibodies against specific cell surface markers on cancer cells and (2) steroid ligands for receptors present in clones of malignant cells. The problems and prospects of these selective delivery systems as potential therapeutic modalities for prostatic cancer are considered.
D000726:Androgen Antagonists / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001895:Boron; D006801:Humans; D007167:Immunotherapy; D007554:Isotopes; D008081:Liposomes / Q000008:administration & dosage; D008297:Male; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011869:Radioligand Assay; D011944:Receptors, Androgen / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D000726:Androgen Antagonists; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007554:Isotopes; D008081:Liposomes; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D001895:Boron